

## Establishing a Basis for Secondary Use Standards for Clinical Trials

[Ernest Odame](#), [Tracy Burgess](#), [Luk Arbuckle](#), [Andrei Belcin](#), [Gwenyth Jones](#), [Peter Mesenbrink](#), [Ramona Walls](#), [Aaron Mann](#)

*Study seeks to understand how different forms of data meet the needs of researchers.*

Secondary use of individual patient data (IPD) generated through a randomized clinical trial (RCT) represents some of the highest-quality research data available. Clinical trial data is collected with the patient's consent from trials designed with clearly defined endpoints derived from objective assessments. Effective reuse of these data has the potential to transform the clinical research process, improve trial design and execution, and respects the patients who donate their time and their data as part of the clinical development process.<sup>1</sup>

To read this study in its entirety, view it in *Applied Clinical Trials*, [here](#).